Clinical Trial Update: Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS) [Phase 2]

View source ↗

Summary

This Phase 2 trial compares two doses of ABT-874 to placebo in individuals with multiple sclerosis. It reports on safety and effectiveness outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• ABT-874 (briakinumab)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED